Mylan expands R&D ops; Merck Serono invests in biotech incubator;

 @FierceBiotech: Fierce's Top 10 Late-Stage Cancer Drugs -- 2012. Report | Follow @FierceBiotech

 @JohnCFierce: GSK doubles down on drug discovery collaboration with FivePrime, a Fierce 15 company in 2004. News | Follow @JohnCFierce

 @RyanMFierce: Google VC fuels Series A round for pharma software startup Wingu, aims to capitalize on open R&D trend. Story | Follow @RyanMFierce

> Mylan ($MYL) is expanding its operations in Ireland, which includes plans to add to its R&D work. Release

> Merck Serono is investing €10 million in a new biotech incubator in Israel. Story

> Biota selected AMRI ($AMRI) to help support its NDA for the influenza antiviral CS8958 (laninamivir), a second-gen neuraminidase inhibitor. Release

Pharma News

 @FiercePharma: Pfizer's still working with Nestle and Danone in nutrition-unit sale, Bloomberg says, though Danone thinks it won't win. Article | Follow @FiercePharma

> J&J plant fixes behind schedule, hampering brands' return. More

> Another day, another deal for Valeant's Pearson. Story

> Mylan pledges 500 new jobs in Irish expansion. News

> Humira sales leap helps power Abbott earnings. Article

Medical Devices News

 @FierceMedDev: Abbott Breakup Plans Are on Target as Profit Tops Estimates | Bloomberg. Article | Follow @FierceMedDev

> As tax looms, device companies mull layoffs, cuts. More

> St. Jude Medical ekes out Q1 sales increase. Story

Drug Delivery News

> Meet the new editor of FierceDrugDelivery. Item

> Novo: Delivery devices could make biosimilars unsafe. More

> Dutch firm gets Fox Foundation funding for PD tech. Story

> BDSI gets patent for anti-opioid film. News

> pSivida stock rallies after Durasert partnerships. Article

Biomarkers News

> Saliva test could aid dentists in oral cancer diagnosis. Story

> Markers may pinpoint blast-induced traumatic brain injuries. Item

> Postmenopausal osteoporosis fingerprinted by miRNAs. More

> Chemo-resistant proteins mark defiant breast tumors. Article

And Finally… UC Santa Barbara researchers have discovered "hypervirulent" versions of Salmonella bacteria that are up to 100 times more capable of triggering disease. Release

 

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.